Biomarkers for immunotherapy in esophageal cancer

Xuelian Wang; Ping Wang; Xiang Huang; Yanan Han; Pei Zhang

doi:10.3389/fimmu.2023.1117523

Biomarkers for immunotherapy in esophageal cancer

Front Immunol. 2023 May 1:14:1117523. doi: 10.3389/fimmu.2023.1117523. eCollection 2023.

Authors

Xuelian Wang¹, Ping Wang², Xiang Huang³, Yanan Han³, Pei Zhang⁴

Affiliations

¹ Department of Oncology and Hematology, Zhongxian People's Hospital, Chongqing, China.
² Department of Urology, Zhongxian People's Hospital, Chongqing, China.
³ Department of Radiation Oncology, The First Center of the Chinese PLA General Hospital, Beijing, China.
⁴ Department of Radiation Oncology, The Fifth Center of the Chinese PLA General Hospital, Beijing, China.

Abstract

The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunotherapy. However, the effects of these reported biomarkers are controversial and many challenges remain. In this review, we aim to summarize the current clinical evidence and provide a comprehensive understanding of the reported biomarkers. We also discuss the limits of the present biomarkers and propose our own opinions on which viewers' discretion are advised.

Keywords: PD-1/PD-L1; biomarker; cancer immunity; esophageal cancer; immunotherapy.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung* / drug therapy
Esophageal Neoplasms* / therapy
Humans
Immunotherapy
Lung Neoplasms* / drug therapy

Substances

Biomarkers, Tumor